Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
This article was originally published in PharmAsia News
Executive Summary
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
You may also be interested in...
Novartis, Roche, AstraZeneca, Sanofi Winners In 2013: China Big Pharma Round-Up
Impacted by compliance issues, Big Pharma’s growth slowed in China. However, Novartis, Roche, AstraZeneca and Sanofi actually gained market share for the year.
Novartis, Roche, AstraZeneca, Sanofi Winners In 2013: China Big Pharma Roundup
Impacted by compliance issues, Big Pharma’s growth slowed in China. However, Novartis, Roche, AstraZeneca and Sanofi actually gained market share for the year.
Asia Spotlight: To Grow Further In China, Big Pharma Needs Innovative Commercial Models
China has now overtaken the U.S. in terms of the number of pharma sales reps employed by MNCs. How to manage such a large sales team in a high-turnover environment with fast-rising costs and declining productivity is a major challenge for Big Pharma, as outlined in a recent McKinsey report.